| __timestamp | Dynavax Technologies Corporation | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 5496000 |
| Thursday, January 1, 2015 | 22180000 | 9786000 |
| Friday, January 1, 2016 | 37257000 | 6792000 |
| Sunday, January 1, 2017 | 27367000 | 7313000 |
| Monday, January 1, 2018 | 64770000 | 8382000 |
| Tuesday, January 1, 2019 | 74986000 | 10803000 |
| Wednesday, January 1, 2020 | 79256000 | 12944000 |
| Friday, January 1, 2021 | 100156000 | 21967000 |
| Saturday, January 1, 2022 | 131408000 | 32810000 |
| Sunday, January 1, 2023 | 152946000 | 46542000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Dynavax Technologies Corporation and Xenon Pharmaceuticals Inc. have showcased distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Dynavax's SG&A expenses surged by an impressive 760%, reflecting its aggressive expansion and strategic investments. In contrast, Xenon Pharmaceuticals exhibited a more conservative growth of 747% in the same period, indicating a steady yet cautious approach.
By 2023, Dynavax's SG&A expenses reached approximately 153 million, dwarfing Xenon's 47 million. This disparity highlights Dynavax's larger operational scale and market ambitions. As these companies continue to evolve, their financial strategies offer valuable insights into the biotech sector's broader economic landscape.
Takeda Pharmaceutical Company Limited and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Dynavax Technologies Corporation Trends and Insights
Ascendis Pharma A/S or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Comparing SG&A Expenses: Pharming Group N.V. vs Xenon Pharmaceuticals Inc. Trends and Insights
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Grifols, S.A. vs Dynavax Technologies Corporation Trends and Insights
ADMA Biologics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Veracyte, Inc. or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Xenon Pharmaceuticals Inc. or Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation